PMID- 38131554
OWN - NLM
STAT- MEDLINE
DCOM- 20231225
LR  - 20240320
IS  - 1998-3689 (Electronic)
IS  - 0301-4738 (Print)
IS  - 0301-4738 (Linking)
VI  - 72
IP  - Suppl 1
DP  - 2024 Jan 1
TI  - Relevance of multicolor imaging, its component channels, and fundus 
      autofluorescence in describing macular telangiectasia type-2 (MacTel) lesion 
      characteristics.
PG  - S125-S134
LID - 10.4103/IJO.IJO_78_23 [doi]
AB  - PURPOSE: The aim of the study was to describe imaging characteristics and 
      detection rates of phenotypic features in macular telangiectasia type-2 (MacTel) 
      on multicolor (MC), blue reflectance (BR), green reflectance (GR), infrared 
      reflectance (IR), and fundus autofluorescence (FAF) and to evaluate sensitivity, 
      specificity, and predictive values across modalities. METHODS: In this 
      monocentric observational study, 282 eyes of 148 patients with MacTel underwent 
      color fundus photograph, MC, BR, GR, IR, FAF, spectral-domain optical coherence 
      tomography (SD-OCT), OCT-angiography (OCT-A), and fundus fluorescein angiography 
      (FFA). Grading was done by two graders qualitatively and quantitatively for the 
      presence of the following prespecified MacTel findings [crystals, right-angle 
      vessels (RAVs), plaques, subretinal neovascularization (SRNV), and MacTel area]. 
      Across each imaging modality, the detection rate of RAVs and SRNV was compared 
      with reference standard OCT-A (RAVs and SRNV) and FFA (SRNV), whereas that of 
      plaques was compared with reference standard SD-OCT. RESULTS: MC identified 
      overall MacTel characteristics in 92.7% of eyes. Regarding the presence, number, 
      and quadrants of RAVs and the presence and number of crystals, MC and GR had 
      superior detection rates as well as the highest sensitivity and negative 
      predictive value. Retinal plaques were better detected using FAF (97%), followed 
      by MC (88%). In proliferative MacTel, SRNV was identified in 86% and 79% of eyes 
      on MC and IR, respectively. While BR clearly delineated MacTel area in 100% eyes, 
      FAF was able to ascertain a larger area of involvement in proliferative MacTel. 
      CONCLUSION: The findings demonstrate the ability of MC, its component channels, 
      and FAF to describe MacTel characteristics qualitatively and quantitatively.
CI  - Copyright (c) 2023 Copyright: (c) 2023 Indian Journal of Ophthalmology.
FAU - Chandran, Kiran
AU  - Chandran K
AD  - Department of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala, 
      India.
AD  - SSM Eye Research Foundation, Giridhar Eye Institute, Cochin, Kerala, India.
FAU - Giridhar, Anantharaman
AU  - Giridhar A
AD  - Department of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala, 
      India.
AD  - SSM Eye Research Foundation, Giridhar Eye Institute, Cochin, Kerala, India.
FAU - Desai, Sachin
AU  - Desai S
AD  - Department of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala, 
      India.
FAU - Gopalakrishnan, Mahesh
AU  - Gopalakrishnan M
AD  - Department of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala, 
      India.
FAU - Indu, V P
AU  - Indu VP
AD  - Department of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala, 
      India.
FAU - Sivaprasad, Sobha
AU  - Sivaprasad S
AD  - NIHR Biomedical Research Centre, Moorfields Eye Hospital, NHS Foundation Trust, 
      London, United Kingdom.
LA  - eng
GR  - MR/P027881/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Observational Study
DEP - 20231222
PL  - India
TA  - Indian J Ophthalmol
JT  - Indian journal of ophthalmology
JID - 0405376
RN  - Idiopathic Juxtafoveal Retinal Telangiectasia
SB  - IM
MH  - Humans
MH  - *Retinal Telangiectasis/diagnosis
MH  - Fundus Oculi
MH  - Retina
MH  - Fluorescein Angiography/methods
MH  - Tomography, Optical Coherence/methods
MH  - *Retinal Neovascularization/diagnosis
PMC - PMC10833168
COIS- There are no conflicts of interest.
EDAT- 2023/12/22 12:42
MHDA- 2023/12/25 06:42
PMCR- 2024/01/01
CRDT- 2023/12/22 07:53
PHST- 2023/01/09 00:00 [received]
PHST- 2023/09/29 00:00 [accepted]
PHST- 2023/12/25 06:42 [medline]
PHST- 2023/12/22 12:42 [pubmed]
PHST- 2023/12/22 07:53 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 02223307-202472001-00023 [pii]
AID - IJO-72-125 [pii]
AID - 10.4103/IJO.IJO_78_23 [doi]
PST - ppublish
SO  - Indian J Ophthalmol. 2024 Jan 1;72(Suppl 1):S125-S134. doi: 
      10.4103/IJO.IJO_78_23. Epub 2023 Dec 22.